CREXONT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CREXONT (CREXONT).
Carbidopa-levodopa combination; levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain, restoring dopaminergic neurotransmission. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa's central availability and reducing peripheral side effects.
| Metabolism | Levodopa is extensively metabolized by aromatic L-amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) peripherally and centrally. Carbidopa inhibits peripheral AAAD. Metabolites include dopamine and 3-O-methyldopa. |
| Excretion | Carbidopa and levodopa are excreted primarily via renal elimination. Carbidopa is excreted largely unchanged (70%) in urine, with the remainder as metabolites. Levodopa is extensively metabolized; its metabolites (including dopamine, 3-O-methyldopa, and others) are excreted renally, accounting for 80% of a dose, with about 20% appearing in feces. |
| Half-life | Levodopa: terminal half-life approximately 1.5 hours (0.75–1.5 h) for immediate-release formulations; with carbidopa co-administration, the half-life is prolonged to about 2 hours. Carbidopa: plasma half-life about 2-3 hours. The short half-life necessitates frequent dosing or extended-release formulations like CREXONT to maintain therapeutic levels. |
| Protein binding | Levodopa: about 10% bound to plasma proteins (primarily albumin). Carbidopa: approximately 30% protein-bound (mainly albumin). |
| Volume of Distribution | Levodopa: apparent Vd approximately 0.9–1.6 L/kg, indicating distribution into total body water and some tissue binding. Carbidopa: Vd about 0.5–1.0 L/kg, reflecting distribution in extracellular fluid. |
| Bioavailability | Oral bioavailability of levodopa is highly dependent on carbidopa. Without carbidopa, bioavailability is about 1-2% due to extensive peripheral decarboxylation. With carbidopa (as in CREXONT, a 1:4 ratio of carbidopa to levodopa), bioavailability increases to approximately 50-60% for the IR component; for the ER component, bioavailability is similar but with a prolonged absorption phase. |
| Onset of Action | Oral administration: Onset of clinical effect (reduction in Parkinsonian symptoms) is typically within 30–60 minutes for IR formulations; for extended-release formulations like CREXONT, onset is delayed to approximately 1–2 hours due to controlled release. |
| Duration of Action | For extended-release (ER) formulations such as CREXONT: duration of effect is approximately 6–8 hours, providing prolonged control of motor symptoms with less fluctuation compared to immediate-release. Clinical note: individual response varies; some patients may require dosing every 5-6 hours. |
For Parkinson's disease: Oral, one capsule of CREXONT (carbidopa 35 mg and levodopa 245 mg extended-release) three times daily initially; may titrate based on response and tolerability. Maximum daily dose: eight capsules (carbidopa 280 mg, levodopa 1960 mg).
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No specific dosage adjustment provided; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation of levodopa metabolites and increased risk of adverse effects. |
| Liver impairment | No specific dosage adjustment provided; use with caution in severe hepatic impairment (Child-Pugh class C) due to altered metabolism. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; not recommended for use in patients <18 years. |
| Geriatric use | Initiate at low end of dosing range; monitor for increased sensitivity to CNS effects (e.g., hallucinations, confusion) and orthostatic hypotension. Consider gradual titration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CREXONT (CREXONT).
| Breastfeeding | Both carbidopa and levodopa are excreted in human breast milk. The milk-to-plasma ratio (M/P) for levodopa is approximately 0.26. The American Academy of Pediatrics considers levodopa/carbidopa compatible with breastfeeding, but caution is advised due to potential adverse effects on the infant (e.g., hematologic suppression, CNS depression). Monitor infant for somnolence, poor feeding, and developmental milestones. |
| Teratogenic Risk | CREXONT (carbidopa/levodopa) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, levodopa caused visceral and skeletal malformations at doses similar to human exposure; carbidopa showed no teratogenic effects. Risk cannot be ruled out. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk of neural tube defects due to folate antagonism. Second and third trimesters: may cause fetal bradycardia and transient neonatal withdrawal symptoms (hypotonia, bradyphrenia). |
■ FDA Black Box Warning
None.
| Serious Effects |
["Concurrent use with nonselective monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing such therapy","Known hypersensitivity to carbidopa, levodopa, or any component of the formulation","Narrow-angle glaucoma (relative; use with caution)","Suspicious undiagnosed skin lesions or history of melanoma (relative)"]
| Precautions | ["May cause dyskinesias, hallucinations, and psychotic-like behavior","Avoid abrupt discontinuation; taper to avoid neuroleptic malignant syndrome (NMS) or akinetic crisis","May cause impulse control disorders (e.g., compulsive gambling, hypersexuality)","May cause orthostatic hypotension, dizziness, or syncope","Caution in patients with history of melanoma or suspicious skin lesions","Levodopa has been associated with somnolence and sudden sleep onset","Risk of glaucoma exacerbation in patients with narrow-angle glaucoma"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of dyskinesia. Assess fetal growth and heart rate via ultrasound and nonstress tests. Monitor for maternal neuropsychiatric effects (hallucinations, depression). Postnatal: assess neonate for withdrawal symptoms (hypotonia, respiratory depression, poor feeding). |
| Fertility Effects | Levodopa may increase prolactin levels, potentially causing galactorrhea and menstrual irregularities. Both carbidopa and levodopa may impair fertility in females due to hormonal alterations. In males, levodopa has been associated with increased libido, but effects on spermatogenesis are unknown. |